Confirmation of model-based dose selection for a Japanese phase III study of rivaroxaban in non-valvular atrial fibrillation patients

Drug Metabolism and Pharmacokinetics

Volumn 28, Issue 4, 2013, Pages 321-331

  Kaneko, Masato ^a   Tanigawa, Takahiko ^a,b   Hashizume, Kensei ^a   Kajikawa, Mariko ^a   Tajiri, Masahiro ^a   Mueck, Wolfgang ^b  

^a BAYER YAKUHIN LTD   (Japan)

^b BAYER PHARMA AG   (Germany)

Author keywords

Anticoagulants; Japanese phase III; PK PD model; Population PK; Rivaroxaban

Indexed keywords

ANTICOAGULANT AGENT; BENZODIAZEPINE DERIVATIVE; CYTOCHROME P450 3A4; DIURETIC AGENT; NONSTEROID ANTIINFLAMMATORY AGENT; OPIATE; PROTEIN INHIBITOR; RIVAROXABAN; WARFARIN;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; BLEEDING; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG SAFETY; FEMALE; HEART ATRIUM FIBRILLATION; HUMAN; JAPAN; MAJOR CLINICAL STUDY; MALE; MAXIMUM PLASMA CONCENTRATION; MULTICENTER STUDY; NON VALVULAR ATRIAL FIBRILLATION; PHASE 3 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

ASIAN CONTINENTAL ANCESTRY GROUP; ATRIAL FIBRILLATION; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; MODELS, BIOLOGICAL; MORPHOLINES; THIOPHENES;

EID: 84878663745     PISSN: 13474367     EISSN: 18800920     Source Type: Journal    
DOI: 10.2133/dmpk.DMPK-12-RG-109     Document Type: Article

References (38)

1. Ohsawa, M., Okayama, A., Sakata, K., Kato, K., Itai, K., Onoda, T. and Ueshima, H.: Rapid increase in estimated number of persons with atrial fibrillation in Japan: an analysis from national surveys on cardiovascular diseases in 1980, 1990 and 2000. J. Epidemiol., 15: 194-196 (2005).
2. Tanizaki, Y., Kiyohara, Y., Kato, I., Iwamoto, H., Nakayama, K., Shinohara, N., Arima, H., Tanaka, K., Ibayashi, S. and Fujishima, M.: Incidence and risk factors for subtypes of cerebral infarction in a general population: the Hisayama study. Stroke, 31: 2616-2622 (2000).
3. Stroke Risk in Atrial Fibrillation Working Group: Independent predictors of stroke in patients with atrial fibrillation: a systematic review. Neurology, 69: 546-554 (2007).
4. Singer, D. E., Albers, G. W., Dalen, J. E., Fang, M. C., Go, A. S., Halperin, J. L., Lip, G. Y. and Manning, W. J.: American College of Chest Physicians. Antithrombotic therapy in atrial fibrillation: American College of Chest Physicians evidence-based clinical practice guidelines (8th Edition). Chest, 133: 546S-592S (2008).
5. Hart, R. G., Pearce, L. A. and Aguilar, M. I.: Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann. Intern. Med., 146: 857-867 (2007).
6. Camm, A. J., Kirchhof, P., Lip, G. Y., Schotten, U., Savelieva, I., Ernst, S., Van Gelder, I. C., Al Attar, N., Hindricks, G., Prendergast, B., Heidbuchel, H., Alfieri, O., Angelini, A., Atar, D., Colonna, P., De Caterina, R., De Sutter, J., Goette, A., Gorenek, B., Heldal, M., Hohloser, S. H., Kolh, P., Le Heuzey, J. Y., Ponikowski, P., Rutten, F. H., Vahanian, A., Auricchio, A., Bax, J., Ceconi, C., Dean, V., Filippatos, G., Funck-Brentano, C., Hobbs, R., Kearney, P., McDonagh, T., Popescu, B. A., Reiner, Z., Sechtem, U., Sirnes, P. A., Tendera, M., Vardas, P. E., Widimsky, P., Vardas, P. E., Agladze, V., Aliot, E., Balabanski, T., Blomstrom-Lundqvist, C., Capucci, A., Crijns, H., Dahlof, B., Folliguet, T., Glikson, M., Goethals, M., Gulba, D. C., Ho, S. Y., Klautz, R. J., Kose, S., McMurray, J., Perrone, F. P., Raatikainen, P., Salvador, M. J., Schalij, M. J., Shpektor, A., Sousa, J., Stepinska, J., Uuetoa, H., Zamorano, J. L. and Zupan, I.: Guidelines for the management of atrial fibrillation: The Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Eur. Heart J., 31: 2369-2429 (2010).
7. Fuster, V., Ryden, L. E., Cannom, D. S., Crijns, H. J., Curtis, A. B., Ellenbogen, K. A., Halperin, J. L., Kay, G. N., Le Huezey, J. Y., Lowe, J. E., Olsson, S. B., Prystowsky, E. N., Tamargo, J. L. and Wann, L. S.: 2011 ACCF/AHA/HRS focused updates incorporated into the ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Circulation, 123: e269-e367 (2011).
8. Japanese Circulation Society Joint Working Group: Guidelines for pharmacotherapy of atrial fibrillation (JCS 2008): digest version. Circ. J., 74: 2479-2500 (2010).
9. Japanese Circulation Society Joint Working Group: Guidelines for management of anticoagulant and antiplatelet therapy in cardiovascular disease (JCS 2009). Nihon Rinsho, 69 Suppl. 9: 567-571 (2011).
10. Ansell, J., Hirsh, J., Hylek, E., Jacobson, A., Crowther, M. and Palareti, G.: Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians evidence-based clinical practice guidelines (8th Edition). Chest, 133:160S-198S (2008).
11. Hylek, E. M.: The need for new oral anticoagulants in clinical practice. J. Cardiovasc. Med. (Hagerstown), 10: 605-609 (2009).
12. Ruff, C. T., Giugliano, R. P., Antman, E. M., Crugnale, S. E., Bocanegra, T., Mercuri, M., Hanyok, J., Patel, I., Shi, M., Salazar, D., McCabe, C. H. and Braunwald, E.: Evaluation of the novel factor Xa inhibitor edoxaban compared with warfarin in patients with atrial fibrillation: design and rationale for the Effective aNticoaGulation with factor xA next GEneration in Atrial Fibrillation-Thrombolysis In Myocardial Infarction study 48 (ENGAGE AF-TIMI 48). Am. Heart J., 160: 635-641 (2010).
13. Lopes, R. D., Alexander, J. H., Al-Khatib, S. M., Ansell, J., Diaz, R., Easton, J. D., Gersh, B. J., Granger, C. B., Hanna, M., Horowitz, J., Hylek, E. M., McMurray, J. J., Verheugt, F. W. and Wallentin, L.: ARISTOTLE Investigators: Apixaban for Reduction In Stroke and Other ThromboemboLic Events in Atrial Fibrillation (ARISTOTLE) trial: design and rationale. Am. Heart J., 159: 331-339 (2010).
14. Connolly, S. J., Ezekowitz, M. D., Yusuf, S., Eikelboom, J., Oldgren, J., Parekh, A., Pogue, J., Reilly, P. A., Themeles, E., Varrone, J., Wang, S., Alings, M., Xavier, D., Zhu, J., Diaz, R., Lewis, B. S., Darius, H., Diener, H. C., Joyner, C. D. and Wallentin, L.: RE-LY Steering Committee and Investigators: Dabigatran versus warfarin in patients with atrial fibrillation. N. Engl. J. Med., 361: 1139-1151 (2009).
15. Connolly, S. J., Ezekowitz, M. D., Yusuf, S., Reilly, P. A. and Wallentin, L.: Newly identified events in the RE-LY trial. N. Engl. J. Med., 363: 1875-1876 (2010).
16. Connolly, S. J., Eikelboom, J., Joyner, C., Diener, H. C., Hart, R., Golitsyn, S., Flaker, G., Avezum, A., Hohnloser, S. H., Diaz, R., Talajic, M., Zhu, J., Pais, P., Budaj, A., Parkhomenko, A., Jansky, P., Commerford, P., Tan, R. S., Sim, K. H., Lewis, B. S., Van Mieghem, W., Lip, G. Y. H., Kim, J. H., Lanas-Zanetti, F., Gonzalez-Hermosillo, A., Dans, A. L., Munawar, M., O'Donnell, M., Lawrence, J., Lewis, G., Afzal, R. and Yusuf, S.: AVERROES Steering Committee and Invetigators. Apixaban in patients with atrial fibrillation. N. Engl. J. Med., 364: 806-817 (2011).
17. Patel, M. R., Mahaffey, K. W., Garg, J., Pan, G., Singer, D. E., Hacke, W., Breithardt, G., Halperin, J. L., Hankey, G. J., Piccini, J. P., Becker, R. C., Nessel, C. C., Paolini, J. F., Berkowitz, S. D., Fox, K. A. A. and Califf, R. M.: ROCKET AF Investigators: Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N. Engl. J. Med., 365: 883-891 (2011).
18. Kubitza, D., Becka, M., Voith, B., Zuehlsdorf, M. and Wensing, G.: Safety, pharmacodynamics, and pharmacokinetics of single doses of BAY 59-7939, an oral, direct Factor Xa inhibitor. Clin. Pharmacol. Ther., 78: 412-421 (2005).
19. Kubitza, D., Becka, M., Wensing, G., Voith, B. and Zuehlsdorf, M.: Safety, pharmacodynamics, and pharmacokinetics of BAY 59-7939-an oral, direct Factor Xa inhibitor-after multiple dosing in healthy male subjects. Eur. J. Clin. Pharmacol., 61: 873-880 (2005).
20. Mueck, W., Eriksson, B. I., Bauer, K. A., Borris, L., Dahl, O. E., Fisher, W. D., Gent, M., Haas, S., Huisman, M. V., Kakkar, A. K., Kälebo, P., Kwong, L. M., Misselwitz, F. and Turpie, A. G. G.: Population pharmacokinetics and pharmacodynamics of rivaroxaban-an oral, direct Factor Xa inhibitor-in patients undergoing major orthopaedic surgery. Clin. Pharmacokinet., 47: 203-216 (2008).
21. Mueck, W., Borris, L. C., Dahl, O. E., Haas, S., Huisman, M. V., Kakkar, A. K., Kälebo, P., Muelhofer, E., Misselwitz, F. and Eriksson, B. I.: Population pharmacokinetics and pharmacodynamics of once-and twicedaily rivaroxaban for the prevention of venous thromboembolism in patients undergoing total hip replacement. Thromb. Haemost., 100: 453-461 (2008).
22. Becker, R., Berkowitz, S. D., Breithardt, G., Califf, R. M., Fox, K., Hacke, W., Halperin, J., Hankey, G., Mahaffey, K., Nessel, C., Singer, D., Ardissino, D., Avezum, A., Aylward, P., Biedermann, B., Breithardt, G., Bode, C., Carolei, A., Corbalán, R., Csiba, L., Dalby, A., Diaz, R., Diener, H. C., Donnan, G., Fox, K., Goodman, S., Hacke, W., Halperin, J., Hankey, G., Heidbüchel, H., Hu, D. Y., Huber, K., Jensen, G., Keltai, M., Lewis, B., López-Sendón, J., MacInnes, G., Mas, JL., Massaro, A., Natale, A., Norrving, B., Penicka, M., Prabhakaran, D., Roine, R., Singer, D., Sirnes, P. A., Skvortsova, V., Steg, P. G., Tan, R. S., White, H., Wong, L., Alpert, J., Boysen, G., Eikelboom, J., Rothwell, P., Skene, A., Pan, G. and Sapp, S. K.: Rivaroxaban-once daily, oral, direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and Embolism Trial in Atrial Fibrillation: rationale and design of the ROCKET AF study. Am. Heart J., 159: 340-347. e1 (2010).
23. Hori, M., Matsumoto, M., Tanahashi, N., Momomura, S., Uchiyama, S., Goto, S., Izumi, T., Koretsune, Y., Kajikawa, M., Kato, M., Ueda, H., Iwamoto, K. and Tajiri, M.: Rivaroxaban versus warfarin in Japanese patients with atrial fibrillation. Circ. J., 76: 2104-2111 (2012).
24. Mueck, W., Becka, M., Kubitza, D., Voith, B. and Zuehlsdorf, M.: Population model of the pharmacokinetics and pharmacodynamics of rivaroxaban-an oral, direct Factor Xa inhibitor-in healthy subjects. Int. J. Clin. Pharmacol. Ther., 45: 335-344 (2007).
25. Mueck, W., Lensing, A. W., Agnelli, G., Decousus, H., Prandoni, P. and Misselwitz, F.: Rivaroxaban: population pharmacokinetic analyses in patients treated for acute deep-vein thrombosis and exposure simulations in patients with atrial fibrillation treated for stroke prevention. Clin. Pharmacokinet., 50: 675-686 (2011).
26. Tanigawa, T., Kaneko, M., Hashizume, K., Kajikawa, M., Ueda, H., Tajiri, M. and Mueck, W.: Model-based dose selection for phase III rivaroxaban study in Japanese patients with non-valvular atrial fibrillation. Drug Metab. Pharmacokinet., 28: 59-70 (2012).
27. Kubitza, D., Becka, M., Roth, A. and Mueck, W.: Dose-escalation study of the pharmacokinetics and pharmacodynamics of rivaroxaban in healthy elderly subjects. Curr. Med. Res. Opin., 24: 2757-2765 (2008).
28. Kubitza, D., Becka, M., Zuehlsdorf, M. and Mueck, W.: Body weight has limited influence on the safety, tolerability, pharmacokinetics, or pharmacodynamics of rivaroxaban (BAY 59-7939) in healthy subjects. J. Clin. Pharmacol., 47: 218-226 (2007).
29. Atarashi, H., Inoue, H., Okumura, K., Yamashita, T., Kumagai, N. and Origasa, H.: Present status of anticoagulation treatment in Japanese patients with atrial fibrillation. Circ. J., 75: 1328-1333 (2011).
30. Rohde, G.: Determination of rivaroxaban-a novel, oral, direct Factor Xa inhibitor-in human plasma by high-performance liquid chromatography-tandem mass spectrometry. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci., 872: 43-50 (2008).
31. Samama, M. M., Martinoli, J. L., LeFlem, L., Guinet, C., Plu-Bureau, G., Depasse, F. and Perzborn, E.: Assessment of laboratory assays to measure rivaroxaban-an oral, direct factor Xa inhibitor. Thromb. Haemost., 103: 815-825 (2010).
32. Beal, S. L., Sheiner, L. B., and Boeckmann A. J.: NONMEM Users' Guides (1989-2008). Ellicot City, Maryland, Icon Development Solutions, 2008.
33. Beal, S. L. and Sheiner, L. B.: Estimating population kinetics. Crit. Rev. Biomed. Eng., 8: 195-222 (1982).
34. DuBois, D. and DuBois, E. F.: A formula to estimate the approximate surface area if height and weight are known. Arch. Intern. Med., 17: 863-871 (1916).
35. Hallynck, T. H., Soep, H. H., Thomis, J. A., Boelaert, J., Daneels, R. and Dettli, L.: Should clearance be normalised to body surface or to lean body mass? Br. J. Clin. Pharmacol., 11: 523-526 (1981).
36. Cockcroft, D. W. and Gault, M. H.: Prediction of creatinine clearance from serum creatinine. Nephron, 16: 31-41 (1976).
37. Gisleskog, P. O., Karlsson, M. O. and Beal, S. L.: Use of prior information to stabilize a population data analysis. J. Pharmacokinet. Pharmacodyn., 29: 473-505 (2002).
38. Zhao, X., Sun, P., Zhou, Y., Liu, Y., Zhang, H., Mueck, W., Kubitza, D., Bauer, R. J., Zhang, H. and Cui, Y.: Safety, pharmacokinetics and pharmacodynamics of single/multiple doses of the oral, direct Factor Xa inhibitor rivaroxaban in healthy Chinese subjects. Br. J. Clin. Pharmacol., 68: 77-88 (2009).